Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

There has been a real interest recently in developing once-daily β2-adrenoceptor agonists
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …

An endogenous defect in β 2-adrenoceptors that results in impaired relaxation of airway
smooth muscle was originally proposed as a putative underlying cause of the asthmatic …

New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …

The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …

There is unequivocal evidence that the combination of an inhaled corticosteroid (ICS)—ie
glucocorticoid—and an inhaled long‐acting β2‐adrenoceptor agonist (LABA) is superior to …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

In the last two decades several significant changes have been proposed in the receptor
theory that describes how ligands can interact with G protein‐coupled receptors (GPCRs) …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …